Elite Pharmaceuticals INC /NV/ (ELTP) — 10-Q Filings

10-Q Filings (6)

• Elite Pharma Swings to Profit on Soaring Manufacturing Revenue — Nov 14, 2025 Risk: medium
  ELITE PHARMACEUTICALS INC /NV/ reported a significant financial turnaround for the six months ended September 30, 2025, achieving a net income of $7,817,692, a
• Elite Pharma Swings to Loss Despite Revenue Surge on Warrant Revaluation — Aug 14, 2025 Risk: high
  ELITE PHARMACEUTICALS INC /NV/ reported a significant increase in total revenue for the three months ended June 30, 2025, reaching $40,211,097, a substantial ri
• Elite Pharmaceuticals Files Q3 2025 10-Q — Feb 13, 2025 Risk: medium
  Elite Pharmaceuticals Inc. reported its third quarter results for the fiscal year ending March 31, 2025. The company's filing covers the period from October 1,
• Elite Pharmaceuticals Files Q2 FY25 10-Q — Nov 14, 2024 Risk: medium
  Elite Pharmaceuticals Inc. reported its financial results for the second quarter of fiscal year 2025, ending September 30, 2024. The company's filing details it
• Elite Pharmaceuticals Files Q1 FY25 10-Q — Aug 14, 2024 Risk: medium
  Elite Pharmaceuticals Inc. filed its 10-Q for the period ending June 30, 2024. The filing covers the first quarter of fiscal year 2025. The company's principal
• Elite Pharmaceuticals Inc. Files 10-Q for Period Ending December 31, 2023 — Feb 14, 2024 Risk: low
  ELITE PHARMACEUTICALS INC /NV/ (ELTP) filed a Quarterly Report (10-Q) with the SEC on February 14, 2024. Elite Pharmaceuticals Inc. filed a 10-Q report for the

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX